COSMOS HEALTH INC

Cosmos Health expands its EU GMP‑certified Athens plant, securing 25 m+ orders across 9 therapeutic categories, boosting recurring profit to $10 m+ and strengthening its global contract‑manufacturing outlook.

Cosmos Health’s “18 Series” promises science‑first nutraceuticals, yet its opaque trials, modest market cap and recent 6% stock dip raise investor questions about credibility and returns.

Cosmos Health Inc. navigates challenges in the healthcare sector, but remains committed to innovation and patient care, positioning itself for future success.

Cosmos Health Inc. is facing significant financial challenges and declining investor confidence, raising questions about its ability to turn its fortunes around and deliver sustainable growth in the competitive healthcare sector.

Cosmos Health Inc. reported a significant turnaround in Q1 2025, with a 54% increase in gross profit and near-breakeven cash flow, driven by a strategic shift towards higher-margin products and operational efficiency.

Cosmos Health Inc’s CEO Greg Siokas has made a bold move by significantly increasing his stake in the company, sparking questions about its future and his vision amidst financial uncertainty.

Cosmos Health Inc. CEO Greg Siokas has made a bold investment in the company, acquiring over 2.7 million shares valued at $1.3 million, demonstrating his confidence in the company’s future prospects and strategic direction.

Cosmos Health Inc. has released its latest quarterly earnings, with its stock price closing at $0.421 USD amidst significant market fluctuations and a competitive healthcare landscape.